Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Somatostatin Receptor Positive (SSTR+)
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Interventions

RADIATION: [177Lu]Lu-DOTA-TATE
DRUG: Octreotide LAR

Sponsor

Novartis Pharmaceuticals